Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE 50 MG ONCE DAILY IN SUBJECTS WITH OVERWEIGHT OR OBESITY (OASIS 1) VERSION 2.0 DATED 20 APRIL 2021

Intervention/treatment:
SEMAGLUTIDE
Medical condition:
OBESITY
Protocol code:
NN9932-4737
Control number:
252451
Status:
Closed
Approved:
June 01, 2021
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05035095
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Reporting Anchor and Disclosure (1452)
Organization
Novo Nordisk A/S
Phone:
(+1) 866-867-7178
Sponsor
NOVO NORDISK CANADA INC

Locations

British Columbia

Ocean West Research Clinic
Surrey, British Columbia, V3Z 2N6

New Brunswick

G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7

Nova Scotia

Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 1V7

Ontario

Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8M 1K7
Wharton Medical Clinic Clinical Trials (Hamilton)
Hamilton, Ontario, L8L 5G8

Results

See the results from the trial NCT05035095. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?